An independent source of information on U.S. brand name drugs for health professionals

Drugdocs Logo

An independent source of information on U.S. brand name drugs for health professionals

HomeDrugsGlossaryAboutContact Us

Menu

HomeDrugsGlossaryAboutContact Us

Drugs A-Z

ABCDE FGHIJKLMNOPQRSTUVWXYZ

DRUGS

A

B

C

D

E

F

G

H

I

J

K

L

M

N

O

P

Q

R

S

T

U

V

W

X

Y

Z

Strensiq

Chemical Nameasfotase alfa
Dosage FormInjection (subcutaneous; 18 mg/0.45 mL, 28 mg/0.7 mL, 40 mg/mL, 80 mg/0.8 mL)
Drug ClassMiscellaneous
SystemMusculoskeletal
CompanyAlexion Pharmaceuticals Inc.
Approval Year2015

Indication

  • To treat perinatal, infantile and juvenile-onset hypophosphatasia (HPP).
Last updated on 10/30/2020

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Strensiq (asfotase alfa) Prescribing Information 2018Alexion Pharmaceuticals, Inc., New Haven, CT
Document TitleYearSource
Asfotase alfa for treating paediatric-onset hypophosphatasia. 2017NICE
Document TitleYearSource
Clinical practice guidelines for hypophosphatasia. 2020Clinical Pediatric Endocrinology